Clinical Trial Update: DLL3 CAR-T Therapy Targeting Brain Tumors [Phase 1, Phase 2]

View source ↗

Summary

This document reports an ongoing phase 1/2 clinical trial of a DLL3-targeted CAR-T therapy for glioblastoma that is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• DLL3 CAR-T therapy

Snippet

Sponsor: Shenzhen Geno-Immune Medical Institute | Conditions: Glioblastoma of Cerebellum | Phase 1, Phase 2 | Status: RECRUITING